Sponsors (10)
The bill strengthens tools and oversight to pressure China and disrupt fentanyl and precursor flows—potentially lowering drug harms—while trading off increased risk of U.S.–China economic retaliation, constraints on certain sanctioning tools, and added administrative burdens that could slow emergency responses.
Border communities and the broader public: The bill strengthens tools (sanctions, accountability for officials, and incentives for China to curb precursor chemical trafficking and improve practices) that could reduce fentanyl and illicit chemical flows and lower drug-related deaths.
Consumers and small businesses that import goods: By exempting imported goods from sanctions, the bill reduces the risk of price spikes or supply shortages and eases trade restrictions on U.S. importers.
Federal oversight and accountability: The bill increases transparency and constraints on emergency sanctions (annual evaluations, defined congressional committees, termination criteria, and cost–benefit analyses), which can limit executive overreach and improve congressional oversight.
Consumers, taxpayers, and businesses: Designations, sanctions, or China’s possible retaliatory export controls could escalate U.S.–China tensions, disrupt supply chains, and raise costs for U.S. consumers and firms.
U.S. national-security policymakers: By prohibiting sanctions that target imported goods, the bill reduces a key leverage tool and limits flexibility to pressure foreign actors tied to illicit supply chains.
Federal agencies and national-security operations: New reporting, committee notifications, and detailed written evaluations could slow fast-moving emergency responses and risk disclosure of sensitive information.
Based on analysis of 5 sections of legislative text.
Expands U.S. sanctions and identification rules to cover PRC entities and officials tied to fentanyl precursor trafficking, increases IEEPA oversight, and bars sanctioning imports of goods under this Act.
Introduced January 28, 2025 by Garland H. Barr · Last progress September 3, 2025
Requires stronger U.S. sanctions and oversight tools targeting Chinese entities and officials involved in producing or facilitating fentanyl precursors, expands the legal definition of foreign opioid traffickers to include certain People’s Republic of China (PRC) entities and senior officials, and presses for China to adopt tighter shipment labeling and "know-your-customer" practices. It also tightens congressional oversight of presidential emergency economic powers used for international drug trafficking and forbids using the bill’s sanctions authorities to block the importation of goods. Adds new identification criteria and longer listing periods for entities and officials tied to precursor trafficking, requires annual presidential evaluations when IEEPA authority is used for drug-trafficking emergencies, and mandates that IEEPA regulations consider costs, benefits, and termination criteria. It stops short of authorizing appropriations and excludes technical data from the statutory definition of "goods."